Vanguard Group Inc Adverum Biotechnologies, Inc. Transaction History

Vanguard Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.5 - $2.33 $190,500 - $295,910	127,000 Added 3.13%	4,189,034 $6.28 Million
Q2 2023 Aug 14, 2023	SELL	$0.68 - $1.59 $55,145 - $128,944	-81,097 Reduced 1.96%	4,062,034 $6.46 Million
Q1 2023 May 15, 2023	BUY	$0.62 - $0.85 $86,862 - $119,085	140,100 Added 3.5%	4,143,131 $2.98 Million
Q4 2022 Feb 10, 2023	BUY	$0.54 - $10.3 $986 - $18,807	1,826 Added 0.05%	4,003,031 $2.32 Million
Q3 2022 Nov 14, 2022	SELL	$0.96 - $9.68 $150,144 - $1.51 Million	-156,400 Reduced 3.76%	4,001,205 $3.8 Million
Q2 2022 Aug 12, 2022	BUY	$0.81 - $1.34 $503,205 - $832,462	621,241 Added 17.57%	4,157,605 $4.99 Million
Q1 2022 May 13, 2022	SELL	$1.23 - $1.95 $871,560 - $1.38 Million	-708,586 Reduced 16.69%	3,536,364 $4.63 Million
Q4 2021 Feb 14, 2022	SELL	$1.74 - $2.4 $232,827 - $321,141	-133,809 Reduced 3.06%	4,244,950 $7.47 Million
Q3 2021 Nov 12, 2021	BUY	$2.08 - $3.6 $68,615 - $118,756	32,988 Added 0.76%	4,378,759 $9.5 Million
Q2 2021 Aug 13, 2021	BUY	$3.36 - $10.56 $14.6 Million - $45.9 Million	4,345,771 New	4,345,771 $15.2 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.